Clinical trials: Dry Syndrome
Dry Eye Syndrome
SYSTANE® Family - Meibomian Deficiency
The purpose of this study was to assess the efficacy of the SYSTANE® family of products (SYSTANE® Lid Wipes, SYSTANE® BALANCE Lubricant Eye Drops, and SYSTANE® Vitamins) on meibomian gland functionality in subjects with lipid…
- Trial name
- M-12-077 (NCT01733745)
- Testing
- SYSTANE® Lid Wipes, SYSTANE® BALANCE, SYSTANE® Vitamins
- Volunteers
- 26 people
- Sponsor
- Alcon Research
Dry Eye
Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.
Phase II, comparative, controlled, multicenter, parallel group, open, randomized clinical study. The main outcome variable will be the Ocular Surface Disease Index (OSDI) questionnaire.
- Trial name
- PRO-037 (NCT04704531)
- Testing
- Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID), Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID), Sodium Hyaluronate Ophthalmic 0.4% Six times per day
- Where
- Mexico
- Volunteers
- 141 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Syndromes
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry…
- Trial name
- NCT02617667
- Testing
- Cyclosporine A
- Where
- 4 sites in United States
- Volunteers
- 207 people
- Sponsor
- Novaliq GmbH
Dry Eye Syndromes
A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants
This study will evaluate the safety, tolerability and efficacy of IC265 compared to vehicle in participants with signs and symptoms dry eye disease.
- Trial name
- NCT05992922
- Testing
- IC265 Ophthalmic Solution 1%
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Iacta Pharmaceuticals
Keratoconjunctivitis Sicca, Dry Eye
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.
- Trial name
- NCT03925727
- Testing
- Tavilermide ophthalmic solution
- Where
- 22 sites in United States
- Volunteers
- 623 people
- Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
Dry Eye Disease
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.
To assess the safety, tolerability and efficacy of a single dose of OTX-CSI, a sustained release cyclosporine drug product, in subjects with dry eye disease.
- Trial name
- NCT04362670
- Testing
- OTX-CSI
- Where
- 15 sites in United States
- Volunteers
- 153 people
- Sponsor
- Ocular Therapeutix, Inc.
Dry Eye, Dry Eye Syndromes
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects…
- Trial name
- NCT04674358
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution
- Where
- United States
- Volunteers
- 329 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dry Eye
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects…
- Trial name
- NCT03916042
- Testing
- Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dry Eye
Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
Dose response related to efficacy and safety of DE-089 ophthalmic solution are examined in patients with dry eye, using a multicenter, randomized, double-blind, parallel group comparison study, and the optimal concentration is…
- Trial name
- NCT01189032
- Testing
- DE-089 ophthalmic solution
- Where
- Japan
- Volunteers
- 320 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Dry Eye Disease
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
Efficacy study of ecabet ophthalmic solution in dry eye disease
- Trial name
- NCT00667004
- Testing
- ecabet ophthalmic solution
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
Evaluation of Clinical Outcomes After the Use of SYSTANE® HYDRATION
The purpose of this study is to compare SYSTANE® HYDRATION to Hyabak 0.15% based on total ocular surface staining scores (TOSS) at Day 42.
- Trial name
- NCT02470429
- Testing
- SYSTANE HYDRATION lubricant eye drops, Hyabak 0.15% eye drops, 0.9% saline eye drops
- Volunteers
- 114 people
- Sponsor
- Alcon Research
Primary Sjögren's Syndrome
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)
- Trial name
- NCT02291029
- Testing
- CFZ533 active - Cohort 1, CFZ533 active - Cohort 2, CFZ533 active -Cohort 3
- Where
- 9 sites in United States, Germany and 3 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Sjögren Syndrome
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome.
- Trial name
- LOUiSSe (NCT04035668)
- Testing
- Remibrutinib
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Syndrome
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT02974907
- Testing
- RGN-259
- Where
- 10 sites in United States
- Volunteers
- 601 people
- Sponsor
- ReGenTree, LLC
Dry Eye Syndromes
Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®
This study will evaluate the efficacy of Restasis® in participants with dry eye disease who engage in electronic visual tasking.
- Trial name
- EMPOWER (NCT02554981)
- Testing
- Cyclosporine 0.05% Ophthalmic Emulsion
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Allergan
Dry Eye Syndrome
SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory Biomarkers
The purpose of this study is to evaluate the ability of SYSTANE® BALANCE and SYSTANE® Gel to improve comfort in subjects with dry eyes.
- Trial name
- NCT01733732
- Testing
- SYSTANE® BALANCE Lubricant Eye Drops, SYSTANE® Gel
- Volunteers
- 54 people
- Sponsor
- Alcon Research
Dry Eye
Confirmatory Study of OPC-12759 Ophthalmic Solution
The purpose of this study is to verify whether OPC-12759 ophthalmic solution is effective compared with placebo in dry eye patients. OPC-12759 ophthalmic suspension will be used as a reference drug.
- Trial name
- NCT01660256
- Testing
- OPC-12759
- Where
- 4 sites in Japan
- Volunteers
- 209 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dry Eye
Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye
This study will access changes in tear protein levels and symptoms of dry eye following insertion of a punctal plug.
- Trial name
- NCT01684436
- Testing
- Punctal Plug
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Allergan
Sjogren's Syndrome
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
This study is a multi-national, multi-center, double-blind (sponsor open), randomized, placebo-controlled trial in subjects with active primary Sjögren's syndrome designed to understand the safety and tolerability profile of…
- Trial name
- NCT02631538
- Testing
- Belimumab, Rituximab
- Where
- 36 sites in Argentina, Canada and 8 more
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Dry Eye Disease (DED)
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
- Trial name
- NCT04036292
- Testing
- OC-01 (varenicline) nasal spray
- Where
- 22 sites in United States
- Volunteers
- 758 people
- Sponsor
- Oyster Point Pharma, Inc.